New drug QRX-3 shows promise in slowing kidney decline in chronic patients
NCT ID NCT06948292
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a new drug, QRX-3, in 127 adults with chronic kidney disease stages 3 to 5. The drug aims to protect kidney cells and improve their function by boosting a natural cell helper called NAD. Over 12 months, researchers measured how fast kidney function declined in people taking QRX-3 compared to those not taking it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
Conditions
Explore the condition pages connected to this study.